Intech Investment Management LLC Purchases Shares of 265,978 DENTSPLY SIRONA Inc. $XRAY

Intech Investment Management LLC acquired a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 265,978 shares of the medical instruments supplier’s stock, valued at approximately $3,375,000.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of DENTSPLY SIRONA by 4.1% in the third quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock valued at $279,263,000 after buying an additional 869,566 shares in the last quarter. AQR Capital Management LLC grew its position in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after acquiring an additional 6,970,086 shares during the period. Lazard Asset Management LLC increased its stake in shares of DENTSPLY SIRONA by 8.0% during the 2nd quarter. Lazard Asset Management LLC now owns 10,107,657 shares of the medical instruments supplier’s stock worth $160,508,000 after purchasing an additional 745,421 shares during the last quarter. State Street Corp raised its holdings in shares of DENTSPLY SIRONA by 5.5% in the 2nd quarter. State Street Corp now owns 7,099,906 shares of the medical instruments supplier’s stock valued at $113,868,000 after purchasing an additional 369,876 shares during the period. Finally, Edmond DE Rothschild Holding S.A. lifted its stake in DENTSPLY SIRONA by 6.0% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 3,087,300 shares of the medical instruments supplier’s stock valued at $49,026,000 after purchasing an additional 173,900 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

Wall Street Analysts Forecast Growth

XRAY has been the topic of a number of recent analyst reports. Zacks Research downgraded DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a research report on Monday, November 10th. Barclays initiated coverage on DENTSPLY SIRONA in a report on Monday, December 8th. They set an “underweight” rating and a $12.00 target price on the stock. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and raised their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Robert W. Baird lifted their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Stifel Nicolaus set a $13.00 price objective on shares of DENTSPLY SIRONA in a research report on Thursday, November 6th. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, DENTSPLY SIRONA currently has a consensus rating of “Hold” and an average target price of $14.00.

Insider Activity

In other news, Director Gregory T. Lucier sold 82,200 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.52% of the stock is currently owned by insiders.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ XRAY opened at $14.68 on Monday. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The stock’s fifty day moving average price is $12.42 and its two-hundred day moving average price is $12.47. DENTSPLY SIRONA Inc. has a one year low of $9.85 and a one year high of $17.34. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -4.89, a P/E/G ratio of 1.19 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The firm had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 26th were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio is presently -21.33%.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.